

NU(Gy)TE.cD.TTm()Tjy (,3 BDC)S3 B BDC BTE H%0 (P)A)g)ó)E)E)G)N)E)I)E)M)B)A)N)E)F)E)I)R)W)P)C)A)G)C)O)3)LS)T) previously acquired by Eisai. The new subsidiary will serve as Eisai's pharmaceutical sales base for the entire Canadian market.

Eisai Limited plans to register and commercialize select products from the Company's U.S. product portfolio including *Opdivo* (Pembrolizumab) (oncology), *Keytruda* (Pembrolizumab) (oncology), *hmc* (generic) (oncology) and

By expanding its sales capabilities in Canada, the ninth largest pharmaceutical market in the world, Eisai aims to strengthen its business operations and presence in the region and independently market its products in accordance with local market needs. The establishment of Eisai Limited not only means that Eisai now has a pharmaceutical sales subsidiary in Canada, it will also allow the Company to prepare for future expansion based on the Company's *hmc* philosophy in both the United States and Canada.

By establishing Eisai Limited, Eisai will make the same supply of high quality, drug products and provision of information.

[Please refer to the following notes to editors]

- Corporate Name: Eisai Limited
- Location: Ontario, Canada
- President: Takihiro Hirasawa
- Scope of Business: Sales and marketing of pharmaceutical products
- Paid-in Capital: 10 million Canadian dollars
- Date of Establishment: April 1, 2010 (Local Time)
- Date of Operation Commencement: May 1, 2010 (Local Time)

h.h.c.